The Institute for Clinical and Economic Review (ICER) released a report on Monday assessing the clinical effectiveness and ...

The Institute for Clinical and Economic Review has prepared a special report on Trelegy and Breo, two therapies that treat ...

The current model for managing chronic obstructive pulmonary disease (COPD) generally considers inhalers from the same therapeutic class to be clinically equivalent.1 When a long-acting muscarinic ...

Obesity is a raging conversation globally now, and manufacturing of generics will pick up after the patent expires.' ...

The demand for inhalation and nasal spray generic drugs is growing as these medications provide affordable and effective treatment options for respiratory ailments like asthma, COPD, and allergies.

Vantage Market Research is pleased to announce the publication of its latest report, Asthma and COPD Drugs Market. This ...

Medicare usually covers the cost of inhalers for people with asthma, COPD, or certain other conditions ... into four tiers based on their costs. Generic medications tend to cost less and occupy ...

Pulmonary Or Respiratory Drug Delivery Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 The Business Research ...

New Delhi: Cancer patients facing prohibitive treatment costs in India can hope for relief: the nation's top drugmakers have ...

Teva has launched new digital inhaler ... generic version of GlaxoSmithKline’s blockbuster inhaler Advair (fluticasone+salmeterol). The competition for the product approved in asthma and COPD ...

Approved yesterday by the FDA, Trelegy Ellipta is the first ever daily single-inhaler to combine a triple therapy for COPD, and could ... as the first Advair generic looks to be just around ...